Table 3.
LDL-C at incident myocardial infarction or stroke in patients with prior cancer by clinical characteristics.
| Myocardial infarction | Stroke | |||
|---|---|---|---|---|
| LDL-C, median (IQR), mmol/L | p value | LDL-C, median (IQR), mmol/L | p value | |
| Sex | ||||
| Male | 2.49 (1.80–3.28) | 0.144 | 2.76 (2.10–3.62) | 0.002 |
| Female | 2.39 (1.74–3.19) | 2.89 (2.22–3.70) | ||
| Cancer TNM staging* | ||||
| I | 2.49 (1.82–3.24) | 0.282 | 2.80 (2.19–3.63) | 0.624 |
| II | 2.41 (1.70–3.10) | 2.70 (2.10–3.56) | ||
| III | 2.50 (1.77–3.31) | 2.80 (2.16–3.70) | ||
| IV | 2.28 (1.60–3.40) | 2.80 (2.09–3.82) | ||
| Duration from cancer diagnosisa | ||||
| 1st quartile | 2.26 (1.53–3.00) | < 0.001 | 2.66 (2.02–3.49) | < 0.001 |
| 2nd quartile | 2.56 (1.90–3.43) | 2.90 (2.25–3.74) | ||
| 3rd quartile | 2.50 (1.86–3.31) | 2.90 (2.20–3.71) | ||
| 4th quartile | 2.40 (1.83–3.19) | 2.81 (2.20–3.65) | ||
| Cancer subtype | ||||
| Head and neck | 2.42 (1.80–3.40) | 0.003 | 3.02 (2.33–4.10) | < 0.001 |
| Upper gastrointestinal | 2.23 (1.43–3.05) | 2.59 (2.00–3.20) | ||
| Hepatobiliary and pancreas | 1.92 (1.42–2.80) | 2.62 (1.82–3.17) | ||
| Colorectal and anal | 2.50 (1.85–3.33) | 2.82 (2.10–3.60) | ||
| Lung and pleura | 2.33 (1.82–3.21) | 2.86 (2.31–3.56) | ||
| Thyroid | 2.32 (1.73–3.34) | 2.79 (2.19–3.60) | ||
| Breast | 2.48 (1.80–3.28) | 2.90 (2.30–3.79) | ||
| Gynaecological (Cervix, ovarian, vagina, endometrial) | 2.32 (1.66–3.14) | 2.98 (2.20–3.77) | ||
| Urological (Kidney and bladder) | 2.55 (1.95–3.31) | 2.90 (2.13–3.63) | ||
| Prostate | 2.48 (1.89–3.20) | 2.68 (2.10–3.55) | ||
| Testicular and penile | 2.60 (2.35–3.96) | 3.00 (2.50–3.66) | ||
| Haematological (Lymphoid and myeloid) | 2.30 (1.61–3.10) | 2.60 (2.00–3.41) | ||
| Central nervous system (Brain, nervous and eye) | 2.85 (1.93–3.97) | 3.17 (2.59–3.70) | ||
| Skin (Melanoma and non-melanoma) | 2.50 (1.87–3.08) | 2.67 (2.09–3.46) | ||
| Others | 2.50 (1.80–3.03) | 2.75 (2.35–3.88) | ||
| Cancer treatmentb | ||||
| Surgery | 2.45 (1.74–3.30) | 0.187 | 2.74 (2.10–3.59) | 0.747 |
| No surgery | 2.35 (1.70–3.14) | 2.75 (2.10–3.60) | ||
| Radiotherapy | 2.40 (1.75–3.25) | 0.689 | 2.90 (2.12–3.82) | 0.012 |
| No radiotherapy | 2.40 (1.71–3.23) | 2.70 (2.10–3.50) | ||
| Chemotherapy | 2.52 (1.80–3.29) | 0.082 | 2.76 (2.12–3.63) | 0.596 |
| No chemotherapy | 2.38 (1.70–3.20) | 2.73 (2.10–3.60) | ||
| Hormone therapy | 2.40 (1.70–3.22) | 0.691 | 2.78 (2.20–3.59) | 0.618 |
| No hormone therapy | 2.40 (1.71–3.24) | 2.73 (2.10–3.60) | ||
| Biological therapy | 2.50 (1.45–3.26) | 0.580 | 2.54 (1.90–3.27) | 0.173 |
| No biological therapy | 2.40 (1.71–3.24) | 2.75 (2.10–3.60) | ||
| Clinical presentation | ||||
| STEMI | 2.75 (2.08–3.52) | < 0.001 | – | – |
| NSTEMI | 2.39 (1.76–3.16) | |||
| Ischaemic stroke | – | – | 2.80 (2.19–3.67) | 0.923 |
| Haemorrhagic stroke | 2.90 (2.12–3.70) | |||
IQR interquartile range, LDL-C low density lipoprotein cholesterol, NSTEMI non ST-segment elevation myocardial infarction, STEMI ST-segment elevation myocardial infarction, TNM tumour node metastasis.
*Details on cancer staging are only available for cancer cases diagnosed from 2003 onwards.
aQuartile range differs between myocardial infarction and stroke cohorts. Myocardial infarction cohort quartiles: 0–715 days, 716–2251 days, 2252–4678 days, > 4678 days. Stroke cohort quartiles: 0–940 days, 941–2829 days, 2830–5526 days, > 5526 days.
bDetails on cancer treatment are only available for cancer cases diagnosed from 2003 onwards; limited to treatment received within the first 6 months from cancer diagnosis.